Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.

Benzinga

New York

United States

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Editas Medicine (NASDAQ:EDIT)

Ad Fontes Media

Media Bias/Fact Check

The Cambridge biotech, the first gene editing company to go public eight years ago, is laying off 180 workers as it focuses strictly on in-vivo, or inside the patient, gene editing.

All Sides

The Business Journals

Advance Publications

Gene-editing pioneer Editas lays off more than half its employees

Despite promising data for its experimental CRISPR treatment, Editas announced a major shift in direction.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

Editas Medicine lays off 65% of staff and shelves lead gene-editing program

Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for an experimental sickle cell therapy, and will halt development on the treatment, the company said Thursday. It plans to turn its focus to in vivo work.

Endpoints News

Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapy

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

Pharmaphorum

Editas axes two-thirds of its staff, including its CMO

The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug candidate reni-cel.

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Editas Medicine (NASDAQ:EDIT)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics